#9301
Re: Novavax (NVAX): Un Nuevo Comienzo
Avisa cuando metas el ultimo, lo mismo me animo. :)
On September 9, 2019, Novavax, Inc. (the “Company”) was informed that the Company would be receiving written notification that the European Medicines
Agency (“EMA”) had concluded that, based on the data package provided under the scientific advice request, the Company would not be able to utilize the
conditional marketing authorization pathway for ResVax in the European Union.